表紙
市場調查報告書
商品編碼
363080

全球雙特異性抗體市場 & 臨床實驗平台考察

Global Bispecific Antibody Market, Drug Sales & Clinical Pipeline Insight 2025

出版日期: | 出版商: KuicK Research | 英文 450 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告涵括全球雙特異性抗體市場,提供在雙特異性抗體概要,作用機制,設計、工程,應用,臨床實驗平台,及上司完畢產品等相關資料,詳細調查分析。

第1章 單株抗體的歷史

第2章 雙特異性單株抗體概要

第3章 雙特異性抗體的作用機制

  • 三官能性抗體:Catumaxomab (Removab®)
  • Blinatumomab

第4章 IgG (免疫球蛋白) 先生雙特異性抗體的設計、工程

第5章 小型雙特異性抗體

第6章 勝過單一特異性單株抗體的雙特異性抗體的優點

第7章 雙特異性抗體的應用

  • 感染疾病診斷BsMAb (雙特異性單株抗體)
  • 癌症診斷BsMAb
  • 阻擋訊號傳達途徑的BsMAb
  • 腫瘤血管新生為目標的BsMAb
  • 對標的的效應器化合物的特異性輸送
  • 雙特異性抗體、基因治療

第8章 全球雙特異性抗體市場概要

  • 目前市場情況
  • 全球雙特異性抗體的臨床開發平台概要

第9章 全球雙特異性抗體市場動態

  • 有利的市場參數
  • 商業化的課題

第10章 全球雙特異性抗體市場未來展望

第11章 全球雙特異性抗體的臨床實驗平台:各企業、症狀、階段

  • 研究階段
  • 前臨床
  • 階段I
  • 階段I/II
  • 階段II
  • 階段III

第12章 已上市雙特異性抗體臨床考察

第13章 臨床實驗平台的中止、停止中的雙特異性抗體:各企業、症狀、階段

  • 中止
  • 無開發報告

第14章 競爭情形

  • Ablynx
  • Adimab
  • Affimed Therapeutics
  • Amgen
  • AstraZeneca (MedImmune)
  • 中外製藥
  • Eli Lilly
  • EMD Serono
  • Emergent BioSolutions
  • Genentech
  • Genmab
  • Immunomedics
  • Jounce Therapeutics
  • MacroGenics
  • Merus
  • Neovii Biotech
  • NovImmune SA
  • OncoMed Pharmaceuticals
  • Pieris
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi
目錄

“Global Bispecific Antibody Market, Drug Sales & Clinical Pipeline Insight 2025” Report Highlights:

  • Applications of Bispecific Antibodies
  • Global Bispecific Antibody Market Overview: Drug & Market Sales
  • Global Bispecific Antibody Market Opportunity: US$ 8 Billion by 2025
  • US & Japan Market Share Opportunity: >40% by 2025
  • Bispecific Antibody Clinical Pipeline: 224 Drugs
  • Commercially Available Bispecific Antibody: 2 (HEMLIBRA & Blincyto)

The research and development of bispecific antibodies has emerged as a new unexplored growth frontier for pharmaceutical industry as per recent research study "Global Bispecific Antibody Market, Drug Sales and Clinical Pipeline Insight 2025" published by Kuick Research. As per report findings, the market opportunity of bispecific antibodies is estimated to surpass US$ 8 Billion by 2025 driven by application of existing commercially available bispecific antibodies to other multiple indications and increasing regulatory approvals from developing and developed markets. Currently, there are 2 bispecific antibodies (HEMLIBRA and Blincyto) commercially available in the market with combined sales of less than US$ 1 Billion in 2018.

The market for bispecific antibodies is quiet bright as they are the new emerging trends in the market. BsAbs due their specificity are gaining a lot of interest from multiple stake holders from the pharmaceutical industry. Now with the improved technology, monoclonal antibody therapy witnessed a drastic transition and is becoming more acceptable due to its site specific approach. They have become a critical component of clinical treatment procedure for a variety of indications.

Therapeutic antibodies in various segments have made the transition from human conception to clinical reality over the past two decades and reached from labs to bedside of the patients. Now, many of mAbs are being tested as adjuvant or first-line therapies to determine their efficacy in improving survival. The market is no doubt flourishing and is sure to increase many folds as with due acceptance of clinicians and patients due to their targeted effect.

Currently, there are more than 200 bispecific antibodies in the clinical trials and this number is further expected to increase in coming years driven by research and development and the favorable commercial success to 2 bispecific antibodies available in the market. Most of bispecific antibodies are being developed for the treatment of multiple cancers followed by infectious disease, CNS disorders, inflammatory and autoimmune disorders. The future for the research and development of bispecific antibodies remains highly progressive and profitable option driven by the fact that increasing number of big and small pharmaceutical companies are allocating their resources and are collaborating with other stake holders of the industry.

Table of Contents

1. History of Monoclonal Antibodies

2. Overview of Bispecific Monoclonal Antibody

3. Mechanism Of Action Of Bispecific Antibody

  • 3.1. Trifunctional Antibody: Catumaxomab (Removab®)
  • 3.2. Blinatumomab

4. The Design & Engineering of IgG like Bispecific Antibodies

  • 4.1. Quadroma (Hybrid Hydromas) Approach
  • 4.2. “Knobs Into Holes” Approach
  • 4.3. CrossMab Approach
  • 4.4. Dual-Variable-Domain Immunoglobulin Approach

5. The Design & Engineering of Small Bispecific Antibodies

  • 5.1. Bispecific Diabodies
  • 5.2. Bispecific T-Cell Engager Antibodies (BiTEs)

6. Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies

7. Applications of Bispecific Antibodies

  • 7.1. BsMAb for Diagnosis of Infectious Diseases
    • 7.1.1. Diagnosis of Bacterial Infections
    • 7.1.2. Diagnosis of Viral Infections
  • 7.2. BsMAb for Cancer Diagnostic
  • 7.3. BsAbs Blocking Signaling Pathways
  • 7.4. BsAbs Targeting Tumor Angiogenesis
  • 7.5. Specific Delivery of Effector Compounds to Targets
  • 7.6. Bispecific Antibodies & Gene Therapy

8. Global Bispecific Antibody Market Overview

  • 8.1. Current Market Scenario
    • 8.1.1. Catumaxomab (Removab)
    • 8.1.2. Blinatumomab
    • 8.1.3. Duligotumab
    • 8.1.4. SAR 156597
  • 8.2. Global Bispecific Antibodies Clinical Pipeline Overview

9. Global Bispecific Antibody Market Dynamics

  • 9.1. Favorable Market Parameters
    • 9.1.1. Target Patient Base
    • 9.1.2. Severity Of The Disease
    • 9.1.3. Unavailability Of Completely Curing Drugs
    • 9.1.4. Side Effects of the Existing Drugs
    • 9.1.5. Specificity of Monoclonal Antibodies in Targeting Cancer Cells
  • 9.2. Commercialization Challenges
    • 9.2.1. Stringent Regulatory Guidelines
    • 9.2.2. Long Duration of Research & Development
    • 9.2.3. Clinical Trial Timeline
    • 9.2.4. High Cost for Research & Development

10. Global Bispecific Antibody Market Future Prospects

11. Global Bispecific Antibodies Clinical Pipeline by Company, Indication & Phase

  • 11.1. Research
  • 11.2. Preclinical
  • 11.3. Phase-I
  • 11.4. Phase-I/II
  • 11.5. Phase-II
  • 11.6. Phase-III

12. Marketed Global Bispecific Antibodies Clinical Insight by Company & Indication

  • 12.1. Emicizumab (HEMLIBRA)
  • 12.2. Blinatumomab (Blincyto)

13. No Development Reported & Discontinued Global Bispecific Antibodies Clinical Pipeline by Company, Indication & Phase

  • 13.1. No Development Reported
  • 13.2. Discontinued
  • 13.3. Market Withdrawal

14. Competitive Landscape

  • 14.1. Ablynx
  • 14.2. Adimab
  • 14.3. Affimed Therapeutics
  • 14.4. Amgen
  • 14.5. AstraZeneca (MedImmune)
  • 14.6. Chugai Pharmaceutical
  • 14.7. Eli Lilly
  • 14.8. EMD Serono
  • 14.9. Emergent BioSolutions
  • 14.10. Genentech
  • 14.11. Genmab
  • 14.12. Immunomedics
  • 14.13. Jounce Therapeutics
  • 14.14. MacroGenics
  • 14.15. Merus
  • 14.16. Neovii Biotech
  • 14.17. NovImmune SA
  • 14.18. OncoMed Pharmaceuticals
  • 14.19. Pieris
  • 14.20. Regeneron Pharmaceuticals
  • 14.21. Roche
  • 14.22. Sanofi

List of Figures

  • Figure 3-1: Mechanism of Action of Bispecific Monoclonal Antibody
  • Figure 3-2: Mechanism of Action of Catumaxomab
  • Figure 3-3: Mechanism of Action of Blinatumomab
  • Figure 4-1: Types of Approaches to Form IgG like Bispecific Antibodies
  • Figure 4-2: Method of Formation of Hybrid Hybridoma
  • Figure 4-3: Limitations of Hybrid Hybridoma
  • Figure 4-4: Steps involved in “Knobs into Holes” Approach
  • Figure 4-5: Three different CrossMabs are Obtained by Three Different Modifications
  • Figure 4-6: Method for formation of Dual-Variable-Domain Immunoglobulin
  • Figure 4-7: Advantages of Dual Variable Domain Immunoglobulin approach
  • Figure 5-1: Types of Bispecific Antibodies
  • Figure 6-1: Advantages of Bispecific Antibodies
  • Figure 7-1: Applications of Bispecific Antibodies
  • Figure 8-1: BLINCYTO - US v/s Rest of World Sales Share (%), 2017
  • Figure 8-2: BLINCYTO - US v/s Rest of World Sales Share (%), Q3'2018
  • Figure 8-3: BLINCYTO - US v/s Rest of World Sales (US$ Million), Q3'2018
  • Figure 8-4: BLINCYTO - Global Sales (US$ Million), Q1'2018 to Q3'2018
  • Figure 8-5: BLINCYTO - US & Rest of World Sales (US$ Million), Q1'2018 to Q3'2018
  • Figure 8-6: Global - Bispecific Antibodies Clinical Pipeline by Phase (%), 2019 till 2025
  • Figure 8-7: Global - Bispecific Antibodies Clinical Pipeline by Phase (Numbers), 2019 till 2025
  • Figure 8-8: Global - Inactive Bispecific Antibodies in Clinical Pipeline by Phase (%),2019 till 2025
  • Figure 8-9: Global - Inactive Bispecific Antibodies in Clinical Pipeline by Phase (Numbers), 2019 till 2025
  • Figure 9-1: Favorable Market Parameters Global Bispecific Antibody Market
  • Figure 9-2: Commercialization Challenges for Bispecific Antibody
  • Figure 10-1: Japan - HEMLIBRA Market Opportunity For Treatment of Hemophilia A ( US$ Million), 2019 - 2025
  • Figure 10-2: Global - HEMLIBRA Market Opportunity For Treatment of Hemophilia A- Inhibitors ( US$ Million), 2019 - 2025
  • Figure 10-3: USA - HEMLIBRA Market Opportunity For Treatment of Hemophilia A- Inhibitors ( US$ Million), 2019 - 2025
  • Figure 10-4: Global - HEMLIBRA Market Opportunity For Treatment of Hemophilia A - Non Inhibitors ( US$ Million), 2019 - 2025
  • Figure 10-5: USA - HEMLIBRA Market Opportunity For Treatment of Hemophilia A - Non Inhibitors ( US$ Million), 2019 - 2025
  • Figure 10-6: Global - Bispecific Antibody Market Opportunity ( US$ Billion), 2019 - 2025
  • Figure 14-1: Ablynx - Clinical Pipeline
  • Figure 14-2: Affimed Therapeutics - Clinical Pipeline
  • Figure 14-3: Amgen - Clinical Pipeline
  • Figure 14-4: EMD Serono - Clinical Pipeline
  • Figure 14-5: Emergent Bioscience - Clinical Pipeline
  • Figure 14-6: Genmab - Clinical Pipeline
  • Figure 14-7: Jounce Therapeutics - Clinical Pipeline
  • Figure 14-8: MacroGenics - Clinical Pipeline
  • Figure 14-9: Merus - Clinical Pipeline
  • Figure 14-10: Novimmune - Clinical Pipeline
  • Figure 14-11: OncoMed - Clinical Pipeline
  • Figure 14-12: Pieris Pharmaceuticals - Clinical Pipeline
  • Figure 14-13: Roche - Clinical Pipeline

List of Tables

  • Table 4-1: List of Bispecific Antibodies Formed by Hybrid Hybridoma Method
  • Table 5-1: List of Bispecific Antibodies Formed by DART
  • Table 5-2: List of Bispecific Antibodies Formed by BiTE Method
  • Table 5-3: List of Other BiTEs
  • Table 7-1: Bispecific Antibodies Targeting Cancer